IGF1R and neoplasm: A strong cytoplasmic immunostaining of tumor cells (cCC-IGF1R 2+) was observed in 202 (13.5%) and a weak cytoplasmic immunostaining (cCC-IGF1R 1+) in 1280 (85.4%) CRCs.